Gregory Haber

Gregory Haber

Auto-generated profile, based on publicly available information

Gregory Haber

Division of Gastroenterology and Hepatology, Department of Medicine, New York University Langone Health, New York, New York, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MDMadhav Desai
Madhav Desai
KAKarlee Ausk
Karlee Ausk
DBDonald Brannan
Donald Brannan
RCRajiv Chhabra
Rajiv Chhabra
WCWalter Chan
Walter Chan
PSPrateek Sharma
Prateek Sharma
INTRODUCTION: Adenoma per colonoscopy (APC) has recently been proposed as a quality measure for colonoscopy. We evaluated the impact of a novel artificial intelligence (AI) system, compared with standard high-definition colonoscopy, for APC measurement. METHODS: This was a US-based, multicenter, prospective randomized trial examining a novel AI detection system (EW10-EC02) that enables a real-time colorectal polyp detection enabled with the colonoscope (CAD-EYE). Eligible average-risk subjects (45 years or older) undergoing screening or surveillance colonoscopy were randomized to undergo either CAD-EYE–assisted colonoscopy (CAC) or conventional colonoscopy (CC). Modified intention-to-treat analysis was performed for all patients who completed colonoscopy with the primary outcome of APC. Secondary outcomes included positive predictive value (total number of adenomas divided by total polyps removed) and adenoma detection rate. RESULTS: In modified intention-to-treat analysis, of 1,031 subjects (age: 59.1 ± 9.8 years; 49.9% male), 510 underwent CAC vs 523 underwent CC with no significant differences in age, gender, ethnicity, or colonoscopy indication between the 2 groups. CAC led to a significantly higher APC compared with CC: 0.99 ± 1.6 vs 0.85 ± 1.5, P = 0.02, incidence rate ratio 1.17 (1.03–1.33, P = 0.02) with no significant difference in the withdrawal time: 11.28 ± 4.59 minutes vs 10.8 ± 4.81 minutes; P = 0.11 between the 2 groups. Difference in positive predictive value of a polyp being an adenoma among CAC and CC was less than 10% threshold established: 48.6% vs 54%, 95% CI −9.56% to −1.48%. There were no significant differences in adenoma detection rate (46.9% vs 42.8%), advanced adenoma (6.5% vs 6.3%), sessile serrated lesion detection rate (12.9% vs 10.1%), and polyp detection rate (63.9% vs 59.3%) between the 2 groups. There was a higher polyp per colonoscopy with CAC compared with CC: 1.68 ± 2.1 vs 1.33 ± 1.8 (incidence rate ratio 1.27; 1.15–1.4; P < 0.01). DISCUSSION: Use of a novel AI detection system showed to a significantly higher number of adenomas per colonoscopy compared with conventional high-definition colonoscopy without any increase in colonoscopy withdrawal time, thus supporting the use of AI-assisted colonoscopy to improve colonoscopy quality (ClinicalTrials.gov NCT04979962).

1 August 2021 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
SMSriHari Mahadev
SriHari Mahadev
AVAshley A. Vareedayah
Ashley A. Vareedayah
SYSofia Yuen
Sofia Yuen
WYWilliam Yuen
William Yuen
KKKristen A. Koller
Kristen A. Koller
GHGregory B. Haber
Gregory B. Haber

13 March 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
AWAndreas Wannhoff
Andreas Wannhoff
ZNZaheer Nabi
Zaheer Nabi
LMLeon M.G. Moons
Leon M.G. Moons
GHGregory Haber
Gregory Haber
PGPhillip S. Ge
Phillip S. Ge
KCKarel Caca
Karel Caca
INTRODUCTION: Nonexposed endoscopic full-thickness resection (EFTR) using a dedicated full-thickness resection device can be used to perform en bloc resection of subepithelial lesions throughout the gastrointestinal tract. In this article, we aim to evaluate the safety and efficacy of EFTR for the management of duodenal neuroendocrine tumors (dNETs). METHODS: This was an international multicenter retrospective study of device-assisted EFTR for dNET. Study outcomes included rates of technical success, R0 resection, and adverse events (AEs). RESULTS: A total of 171 patients were included across 35 centers. Lesions had a median size of 10 mm and were in the duodenal bulb in 143 cases (83.6%). Technical success was achieved in 164 (95.9%) and R0 resection in 123 cases (71.9%). The R0 resection rate for lesions located in the proximal third of the bulb was 62.0% compared with 83.9% for more distal locations ( P = 0.002). The R0 resection rate was not affected by lesion size or depth of invasion. On multivariable analysis, date of resection (2021 onward) and location distal to the proximal third of the duodenal bulb were independent predictors of R0 resection, but not case volume per participating center. Follow-up information was available for 114 patients (66.7%) and demonstrated 2 recurrences over a median follow-up of 10 months. Severe AEs occurred in 3 patients (1.8%). DISCUSSION: EFTR of dNET showed high technical success and R0 resection rates and very low rate of severe AEs. It could become endoscopic treatment of choice for dNET, at least for lesions not within proximity of the pylorus.

27 June 2025 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
OCOliver Cronin
Oliver Cronin
KMKayla Meys
Kayla Meys
SYSofia Yuen
Sofia Yuen
AVAbhinav Vij
Abhinav Vij
TGTamas Gonda
Tamas Gonda
GHGregory B. Haber
Gregory B. Haber

28 March 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SDSue Dong
Sue Dong
EAEmil Agarunov
Emil Agarunov
MFMatthew Fasullo
Matthew Fasullo
KKKi-Yoon Kim
Ki-Yoon Kim
LKLauren Khanna
Lauren Khanna
TGTamas A. Gonda
Tamas A. Gonda
INTRODUCTION: We sought to determine the yield of somatic mutational analysis from endoscopic ultrasound (EUS)-guided biopsies of pancreatic adenocarcinoma compared with that of surgical resection and to assess the impact of these results on oncologic treatment. METHODS: We determined the yield of EUS sampling and surgical resection. We evaluated the potential impact of mutational analysis by identifying actionable mutations and its direct impact by reviewing actual treatment decisions. RESULTS: Yield of EUS sampling was 89.5%, comparable with the 95.8% yield of surgical resection. More than a quarter in the EUS cohort carried actionable mutations, and of these, more than 1 in 6 had treatment impacted by mutational analysis. DISCUSSION: EUS sampling is nearly always adequate for somatic testing and may have substantial potential and real impact on treatment decisions.

1 June 2018 in Gastrointestinal Endoscopy
Verified
Journal Article
Open access
PDF file
ALAli Lankarani
Ali Lankarani
Guido CostamagnaGuido Costamagna
Guido Costamagna
Ivo BoskoskiIvo Boskoski
Ivo Boskoski
JNJose Nieto
Jose Nieto
GLGlen A. Lehman
Glen A. Lehman
PTPier Alberto Testoni
Pier Alberto Testoni
The aim of this study is to assess the long term efficacy and safety of endoscopic anterior fundoplication (EAF) using MUSE™ (Medigus Ultrasonic Surgical Endostapler) for GERD management.